Page last updated: 2024-12-06

calcium pyrophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Calcium Pyrophosphate: An inorganic pyrophosphate which affects calcium metabolism in mammals. Abnormalities in its metabolism occur in some human diseases, notably HYPOPHOSPHATASIA and pseudogout (CHONDROCALCINOSIS). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164806
MeSH IDM0003179
PubMed CID24632
CHEBI ID32598
MeSH IDM0003179

Synonyms (60)

Synonym
thomas phosphate
1306-01-0
einecs 215-143-6
unii-cj64n85j4s
cj64n85j4s ,
tetracalcium phosphate
DTXSID50926827
calcium oxide phosphate (4/1/2)
tetracalcium;oxygen(2-);diphosphate
thomas phosphate [mi]
tetracalcium oxide diphosphate
calcium oxide phosphate (ca4o(po4)2)
calcium phosphate, tetrabasic
calcium oxide bis(phosphate)
Q21099587
calcium;calcium;oxygen(2-);phosphane
calcium oxide phosphate
7790-76-3
calcium pyrophosphate
calcium diphosphate
ca2p2o7
35405-51-7
CHEBI:32598
calcium pyrophosphate, tetrabasic (form ii)
calcium pyrophosphate, tetrabasic (form i)
calcium phosphono dihydrogen phosphate
calcium phosphate (ca2p2o7)
10086-45-0
unii-x69nu20d19
diphosphoric acid, calcium salt
diphosphoric acid, calcium salt (1:2)
dicalcium pyrophosphate
calcium pyrophosphate (ca2p2o7)
x69nu20d19 ,
ec 232-221-5
pyrophosphoric acid, calcium salt (1:2)
alpha-calcium pyrophosphate
hsdb 1435
einecs 232-221-5
AKOS015902785
calcium phosphate, amorphous
diphosphoric acid, dicalcium
calcium pyrophosphate [fcc]
calcium pyrophosphate [inci]
calcium pyrophosphate [who-dd]
calcium pyrophosphate [ii]
calcium pyrophosphate [mi]
calcium pyrophosphate [hsdb]
JUNWLZAGQLJVLR-UHFFFAOYSA-J
calciumpyrophosphate
diphosphoric acid,calcium salt (2:1)
DTXSID50872512
mfcd00015983
FT-0727361
Q4363460
dicalcium;phosphonato phosphate
calcium phosphate (pyro)
1264298-55-6
calcium pyrophosphate (99.95%-ca)
dicalcium (phosphonatooxy)phosphonate

Research Excerpts

Effects

ExcerptReferenceRelevance
"beta-calcium pyrophosphate has been used as a bone-graft extender. "( A 90-day subchronic toxicity study of beta-calcium pyrophosphate in rat.
Chang, BS; Lee, CK; Lee, JH; Ryu, HS, 2009
)
1.13

Toxicity

ExcerptReferenceRelevance
" The results show no adverse toxic effects of beta-calcium pyrophosphate extract (30 mg/kg body weight/day) for rats of either sex."( A 90-day subchronic toxicity study of beta-calcium pyrophosphate in rat.
Chang, BS; Lee, CK; Lee, JH; Ryu, HS, 2009
)
0.87

Compound-Compound Interactions

ExcerptReferenceRelevance
"The purpose of this study was to investigate the efficacy of BCP granules combined with rhBMP-2 for ectopic bone formation in rats."( [Ectopic bone induction in recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with biphasic calcium phosphate (BCP)].
Higuchi, T; Ishikawa, I; Kinoshita, A; Oda, S; Shizuya, T, 1996
)
0.29
"Tricalcium phosphate (TCP) was combined with amylopectin to form a deliverable carrier paste for recombinant human transforming growth factor beta 1 (rhTGF-beta 1) intended for bone repair applications."( Development of tricalcium phosphate/amylopectin paste combined with recombinant human transforming growth factor beta 1 as a bone defect filler.
Beck, LS; DeGuzman, L; Lee, WP; Nguyen, T; Ongpipattanakul, B; Osaka, G; Wong, R; Zioncheck, TF, 1997
)
0.3
"We investigated ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) in the rat dorsum."( Ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2).
Higuchi, T; Ishikawa, I; Kinoshita, A; Oda, S; Shizuya, T, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
"A consumer test and standardized methods were compared for measuring the disintegration of calcium tablets, and the disintegration results were compared with results of dissolution testing to determine the ability of the consumer test of disintegration to predict bioavailability of calcium."( Consumer vinegar test for determining calcium disintegration.
Dressman, JB; Mason, NA; Patel, JD; Shimp, LA, 1992
)
0.28
"In the present study, we compared the bioavailability of various calcium salts in the diet such as calcium lactate, calcium carbonate and calcium phosphate by examining the effects of these calcium salts on serum calcium concentration and on the mineralization of incisor dentin in parathyroidectomized (PTXed) rats."( [Comparisons of bioavailability of various calcium salts. Utilization incisor dentin in parathyroidectomized rats].
Arai, M; Kohsaka, M; Matsumoto, S; Ohira, T; Takei, H; Togari, A; Yamaguchi, M, 1989
)
0.28
" Slope-ratio techniques using tibia ash and total nonphytin phosphorus intake established the bioavailability of phosphorus from precipitated bone was 120% when dicalcium phosphate was the standard."( Precipitated bone phosphate in broiler chick diets.
Damron, BL; Flunker, LK, 1988
)
0.27
" eutrophus strain CH34, was shown to interact with Cd and consequently affect its bioavailability and toxicity."( Effect of the siderophore alcaligin E on the bioavailability of Cd to Alcaligenes eutrophus CH34.
Baeyens, W; Corbisier, P; Gilis, A; Mergeay, M; Taghavi, S; van der Lelie, D, 1998
)
0.3
"We evaluated the bioavailability of two types of calcium from milk in two experiments."( Bioavailability of milk micellar calcium phosphate-phosphopeptide complex in rats.
Aoe, S; Aoki, T; Kato, K; Nakano, T; Takada, Y; Tanaka, M; Toba, Y, 1999
)
0.3
"Calcium-fortified soy milk is growing in popularity, particularly among vegetarians, but the bioavailability of its calcium was not previously known."( Bioavailability of the calcium in fortified soy imitation milk, with some observations on method.
Bierman, J; Dowell, MS; Heaney, RP; Rafferty, K, 2000
)
0.31
"The objectives of this study were to compare the bioavailability of the calcium in fortified soy milk with that of calcium in cow milk and to evaluate the method of labeling soy milk for bioavailability testing."( Bioavailability of the calcium in fortified soy imitation milk, with some observations on method.
Bierman, J; Dowell, MS; Heaney, RP; Rafferty, K, 2000
)
0.31
"Calcium-fortified soy milk does not constitute a calcium source comparable to cow milk, and extrinsic labeling of such calcium particulate suspensions does not produce the uniform tracer distribution needed for bioavailability testing."( Bioavailability of the calcium in fortified soy imitation milk, with some observations on method.
Bierman, J; Dowell, MS; Heaney, RP; Rafferty, K, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" These dramatic bone changes were all significantly increased at the dose-response manner."( Production of new trabecular bone in osteopenic ovariectomized rats by prostaglandin E2.
Jee, WS; Li, XJ; Mori, S, 1992
)
0.28
" The present study was undertaken to examine early changes in vascular ultrastructure of rats receiving tap water supplemented with either calcium chloride or a relatively low dosage of irradiated ergocalciferol ad libitum for 21 days."( Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats.
Kingma, JG; Roy, PE, 1988
)
0.27
" In these patients it is of importance to modify the drug dosage or to abandon the prophylaxis when it interferes with the metabolic changes of renal function impairment."( [Prevention of calculus recurrence in impaired kidney function].
Hautmann, R, 1984
)
0.27
" Compression load and dose-response studies were conducted for a total duration of seven days."( A ceramic system for continuous release of acetylsalicylic acid.
Bajpai, PK; Moldovan, KM, 1994
)
0.29
" Four studies examined the effects of different concentrations of fluoride, established dose-response profiles with NaF and Na2PO3F, and tested commercial dentifrices."( An in vitro model for studying the efficacy of fluoride dentifrices in preventing root caries.
Beiswanger, AJ; Dunipace, AJ; Stookey, GK; Zhang, W, 1994
)
0.29
" Twenty Wistar rats were separated into 4 groups consisting of 5 animals each dosed with 2, 10, and 50 micrograms/700 microliters of rhBMP-2 and a control group (BCP only)."( Ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2).
Higuchi, T; Ishikawa, I; Kinoshita, A; Oda, S; Shizuya, T, 1997
)
0.3
"Although further studies are necessary regarding the effects of etidronate on crystallization and crystal adhesion both in vivo and in vitro, and the appropriate schedule of dosing to prevent side effects, it is possible that etidronate may be useful in the treatment of urinary stones."( Effects of etidronate disodium on crystallizations in synthetic urine and calcium oxalate crystal adhesion to Madin-Darby canine kidney (MDCK) cells.
Ebisuno, S; Inagaki, T; Kohjimoto, Y; Komura, T; Nishihata, M; Nishikawa, T; Ohkawa, T, 1998
)
0.3
" Reductions were greatest among patients being treated with antihypertensive medications, despite a reduction in their dosage of medications."( Clinical and biochemical correlates of starting "daily" hemodialysis.
Buoncristiani, U; Held, PJ; Orzol, S; Port, FK; Wolfe, RA; Woods, JD; Young, E, 1999
)
0.3
"A floating dosage form composed of nicardipine hydrochloride (NH) and hydroxypropylmethylcellulose acetate succinate (enteric polymer) was prepared using a twin-screw extruder."( Evaluation of a floating dosage form of nicardipine hydrochloride and hydroxypropylmethylcellulose acetate succinate prepared using a twin-screw extruder.
Fukui, H; Izumi, S; Nakamichi, K; Oka, M; Yasuura, H, 2001
)
0.31
"05), despite drug dosage did not differ."( [Seasonal profile of calcium-phosphate metabolism in hemodialysis patients with secondary hyperparathyroidism].
Doroszewski, W; Kretowicz, M; Manitius, J; Odrowaz-Sypniewska, G; Strózecki, P, 2002
)
0.31
" An increase in the dosage of phage particles, up to at least 5 x 10(7) phage particles per 100-mm dish, resulted in a linear increase in the number of transformants."( Phage particle-mediated gene transfer to cultured mammalian cells.
Hamada, Y; Hirose, S; Ishiura, M; Okada, Y; Suzuki, Y; Uchida, T, 1982
)
0.26
" Measurement of urinary excretion of EHDP was used to define the best dosage regimen."( Biochemical and clinical effects of ethane-1-hydroxy-1,1-diphosphonate in calcium nephrolithiasis.
Baumann, JM; Bisaz, S; Fleisch, H; Wacker, M, 1978
)
0.26
" Information about colchicine dosing and clinical outcomes, with particular attention to interventions by Rheumatologists, was obtained."( Intravenous colchicine use in crystal-induced arthropathies: a retrospective analysis of hospitalized patients.
Maldonado, MA; Salzman, A; Varga, J,
)
0.13
"Intravenous colchicine dosing schedules generally followed recommended guidelines."( Intravenous colchicine use in crystal-induced arthropathies: a retrospective analysis of hospitalized patients.
Maldonado, MA; Salzman, A; Varga, J,
)
0.13
" All patients underwent a complete clinical examination, a US examination of the affected joint, arthrocentesis of the knee and analysis of synovial fluid, including dosing of inorganic ions and number of crystals."( The two faces of the same medal… or maybe not? Comparing osteoarthritis and calcium pyrophosphate deposition disease: a laboratory and ultrasonographic study.
Adinolfi, A; Bortoluzzi, A; Filippou, G; Frediani, B; Govoni, M; Picerno, V; Punzi, L; Scanu, A; Scirè, CA; Toscano, C,
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
calcium phosphateA calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (2,751)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990733 (26.64)18.7374
1990's1036 (37.66)18.2507
2000's647 (23.52)29.6817
2010's229 (8.32)24.3611
2020's106 (3.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 106.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index106.37 (24.57)
Research Supply Index7.01 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index196.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (106.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials57 (3.10%)5.53%
Trials15 (1.38%)5.53%
Reviews111 (6.04%)6.00%
Reviews189 (17.39%)6.00%
Case Studies88 (4.79%)4.05%
Case Studies252 (23.18%)4.05%
Observational0 (0.00%)0.25%
Observational6 (0.55%)0.25%
Other1,583 (86.08%)84.16%
Other625 (57.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]